Serotypes and Clonal Diversity of Streptococcus pneumoniae Causing Invasive Disease in the Era of PCV13 in Catalonia, Spain

PLoS One. 2016 Mar 8;11(3):e0151125. doi: 10.1371/journal.pone.0151125. eCollection 2016.

Abstract

The aim of this study was to study the serotypes and clonal diversity of pneumococci causing invasive pneumococcal disease in Catalonia, Spain, in the era of 13-valent pneumococcal conjugate vaccine (PCV13). In our region, this vaccine is only available in the private market and it is estimated a PCV13 vaccine coverage around 55% in children. A total of 1551 pneumococcal invasive isolates received between 2010 and 2013 in the Molecular Microbiology Department at Hospital Sant Joan de Déu, Barcelona, were included. Fifty-two serotypes and 249 clonal types-defined by MLST-were identified. The most common serotypes were serotype 1 (n = 182; 11.7%), 3 (n = 145; 9.3%), 19A (n = 137; 8.8%) and 7F (n = 122; 7.9%). Serotype 14 was the third most frequent serotype in children < 2 years (15 of 159 isolates). PCV7 serotypes maintained their proportion along the period of study, 16.6% in 2010 to 13.4% in 2013, whereas there was a significant proportional decrease in PCV13 serotypes, 65.3% in 2010 to 48.9% in 2013 (p<0.01). This decrease was mainly attributable to serotypes 19A and 7F. Serotype 12F achieved the third position in 2013 (n = 22, 6.4%). The most frequent clonal types found were ST306 (n = 154, 9.9%), ST191 (n = 111, 7.2%), ST989 (n = 85, 5.5%) and ST180 (n = 80, 5.2%). Despite their decrease, PCV13 serotypes continue to be a major cause of disease in Spain. These results emphasize the need for complete PCV13 vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Child
  • Child, Preschool
  • Female
  • Genetic Variation
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Multilocus Sequence Typing
  • Pneumococcal Infections / epidemiology*
  • Pneumococcal Infections / microbiology*
  • Pneumococcal Infections / prevention & control
  • Pneumococcal Vaccines / immunology
  • Serogroup
  • Spain / epidemiology
  • Streptococcus pneumoniae / classification*
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / genetics*
  • Streptococcus pneumoniae / immunology
  • Young Adult

Substances

  • 13-valent pneumococcal vaccine
  • Anti-Bacterial Agents
  • Pneumococcal Vaccines

Grants and funding

This work was supported by FEDER and the Ministry of Science and Innovation, Institute of Health Carlos III, Projects of Research on Health (FIS project number PI13/01729), Godia Foundation and Sant Joan de Deu Foundation. EdA was the recipient of a fellowship from Instituto de Salud Carlos III (PFIS0100). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.